2022年10月7日

新加坡，2022年10月7日/美通社/——萊佛士醫療集團(RMG)正在與生物技術初創公司NalaGenetics合作，在其醫院提供先發製人的藥物基因組學測試。這是新加坡第一家提供此類服務的醫院。藥物基因組學是研究基因如何影響一個人對藥物的反應。對健康人進行先發製人的藥物基因組學測試可用於發現一個人是否可能對某些藥物反應良好或產生不良藥物反應(adr)。測試結果可以用來指導醫生對藥物的選擇和劑量，以改善患者的預後。RMG和NalaGenetics之間的合作涉及招募500名患者參與預防性藥物基因組學測試的試點研究，涵蓋心血管、精神病學和疼痛等方麵的一係列慢性處方。該研究旨在更好地了解醫生如何利用這些信息，同時為在新加坡大規模實施的潛在好處提供研究數據。這項研究將進行一年多，招聘將於10月3日開始。患有或易患十種特定疾病的患者將有資格參加這項研究。符合條件的參與者將在新加坡萊佛士醫院通過非侵入性口腔拭子收集他們的基因樣本，然後由NalaGenetics在其實驗室進行測試。 The test results will be integrated into the participants' electronic medical records at RMG. There is no cost involved to participate in the study. RMG will also avail the testing as a commercial service to other interested patients or members of the public, with NalaGenetics as the testing partner. Such commercial testing will cover a much wider range of medications. Benefits of pre-emptive pharmacogenomics testing Providing pre-emptive pharmacogenomics testing is timely as Singapore is increasingly focusing on preventive health. Such testing could help to identify high-risk patients and avert side effects and even hospital admissions. For example, patients who have genetics that put them at risk of not being able to metabolise blood thinners well are up to two times more likely to experience recurring acute coronary syndrome[1]. Research has also shown that 8% of hospital admissions are caused by ADRs and 30% of those have high genetic associations, and patients with ADRs have a longer length of stay on average[2]. "RMG is the first hospital in Singapore to offer pre-emptive pharmacogenomics testing. We believe that a patient's genetic information can help facilitate our doctors' decision-making process and result in more appropriate prescriptions and better patient outcomes. As a leading integrated healthcare provider, we have always leveraged technology to enhance patient care, and this innovative collaboration with NalaGenetics is yet another value-added service for our patients," says Dr. Chng Shih Kiat, Medical Director, Raffles Medical. "We believe that pre-emptive pharmacogenomics testing not just improves outcomes for patients, it also helps in cutting healthcare costs by avoiding inappropriate treatments. There are potentially long-term cost savings from implementing such pre-emptive testing on a large-scale for governments and insurance companies," says Ms Levana Sani, CEO of NalaGenetics. She added, "This collaboration with RMG is very exciting for our team, because we get to implement our system end-to-end; from patient recruitment all the way to integration of patient reports to help physicians not only at the point of testing, but throughout the patient's health journey." Those interested in taking the test can contact Raffles Health Screeners at Raffles Hospital. [1] https://www.ahajournals.org/doi/10.1161/JAHA.121.024159